the blood clot in the left atrial appendage when the patient stops taking warfarin

In the API-CAT trial involving patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for preventing recurrent thromboembolic events. Full trial results and Research Summary:

#API-CAT Study study just published in NEJM

Big congrats to Stephan Nopp on his successful PhD defense! 🎓👏 It was a real pleasure working with you – smart, dedicated, and a true team player. Wishing you all the best for what’s next!

🤣🤣🤣🤣🤣 C’est lunaire Les mecs insultent l’IA qui leur affirme que Pr Mathieu Molimard dit vrai 🤣🤣🤣🤣

🧬 🔬 Notre nouveau papier dans Scientific Reports identifie le biomarqueur sST2 comme biomarqueur pour prédire l’évolution clinique COVID-19 dans l’essai #DisCoVeRy 🇪🇺 📖 nature.com/articles/s4159… #COVID19 #EUResponse #endotheliopthy #ST2

Merci 🤣 ça m’a fait ma soirée ✨ J’ai des crampes abdominales à force de rire 😂 Les désinformateurs qui pensent qu’ils sont pris pour des cons par l’IA, c’est collector 🧠🤡

New RPTH Research Recap alert! Join us for the upcoming May 13 Recap as we dive into the latest findings on COVID-19, anti-PF4/heparin antibodies, and platelet activation. 🔗 Learn more and register here: bit.ly/4iA2sZx

Best. Present. Ever.

Arrêtez tout, j’ai trouvé le boss ultime ! (Qui coûte un fric fou à la sécu car il prescrit des analyses dans tous les sens, parfaitement inutiles)

🚨Next ISTH RPTH Research Recap! 🗓️May 13 | 16:00 UTC Nicolas Gendron & Frederik Denorme discuss the RPTH article: Relevance of anti-PF4/H antibodies & platelet activation in syst. inflam. diseases & thromb. dis.: insight f/t COVID19 pandemic. bit.ly/42TBW7y

« A jeun depuis 12h, ne pas boire même un verre d’eau » Consigne débile, infondée*, dangereuse. #LaBiologieCestUnMétier

🍷❤️‍🩹Alcohol Use and Cardiovascular Disease: A Scientific Statement From the American Heart Association | Circulation ahajournals.org/doi/10.1161/CI…

Excited for this one! Love to see #ISTH2025 including sessions on #AnticoagStewardship Lana Castellucci

SSC on Control of Anticoagulation Message #1: monitoring patients on UFH who have been on direct Xa inhibitors is challenging. The drugs hang around for days and interfere with anti Xa assays. #ISTH2025 THANZ

ISTH is inviting all clinicians involved in anticoagulation management to participate in the following survey: redcap.slhd.nsw.gov.au/surveys/?s=7K4… These are the outcomes they are interested in. Jump on the link and fill it out! #ISTH2025 THANZ

Utiliser un monitoring avec anti-Xa plutôt que aPTT avec l’héparine non fractionnée thérapeutique ? Proposition qui demeure à être validée. #ISTH2025

Is this the end of rivaroxaban for acute VTE? Lana Castellucci presenting the COBBRA trial - 1st RCT comparing apixaban to riva over 3 months. 56% reduction in bleeding risk with apixaban. A safer Rx with the same efficacy. #ISTH2025

🩸 Meta-analysis presented at #ISTH2025 and simultaneously published in EHJ Editor-in-Chief found that several risk factors (e.g., previous history of VTE or bleeding, advanced cancer, and specific cancer sites) are associated with recurrent VTE and bleeding in patients with CAT.

Outstanding Margareta Blombäck Memorial Plenary Lecture on Genetics of venous thrombosis: focus on coagulation factors and co-factors! Congratulations, Pierre Morange pierre morange ! #ISTH2025 pierre morange ISTH